STOCK TITAN

Olma Health (NASDAQ: OLMA) director reports several stock sales in Jan–Feb 2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Olma Health affiliate transactions: Shane W. Kovacs reported multiple sales of Common stock totaling several tranches in January–February 2026. The filing lists individual sales such as 100,000 shares on 01/15/2026 and smaller tranches on other dates, with cash proceeds shown per trade.

Positive

  • None.

Negative

  • None.

Insights

Multiple affiliate sales by a named insider are recorded over weeks in early 2026.

The filing itemizes discrete Common stock dispositions by Shane W. Kovacs across dates in January–February 2026, including a 100,000 share trade on 01/15/2026. Each row shows share counts and gross proceeds per trade.

These entries are transactional disclosures; cash‑flow treatment and whether trades were preplanned are not stated in the excerpt. Subsequent filings or broker reports would be needed for further context.

The form provides granular sale dates, share counts, and proceeds but does not aggregate totals.

The table lists trade dates, share amounts (for example 3,822, 100,000, 30,000) and dollar proceeds for each trade. No clause in the excerpt claims aggregated totals or exemptions.

Regulatory reviewers typically treat each row as an individual disposition; any compliance assessment should reference the full filing and broker confirmations.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What securities did OLMA report for sale in this Form 144?

The filing lists sales of Common stock. It shows multiple dispositions by Shane W. Kovacs across January and February 2026, with each trade reported as Common shares and corresponding gross proceeds per trade.

How many shares did Shane W. Kovacs sell on 01/15/2026 according to the filing?

The filing shows a sale of 100,000 Common shares on 01/15/2026. The row lists that trade's share count and associated gross proceeds as reported in the table.

What proceeds are shown for the 02/23/2026 and 02/24/2026 trades?

The filing records gross proceeds of $723,007.46 for the 02/23/2026 trade and $500,002.00 for the 02/24/2026 trade, each tied to the listed share amounts in the table.

Does the Form 144 aggregate total shares sold by the insider?

The excerpt provides individual trade rows with share counts and proceeds but does not present an explicit aggregated total. Each disposition is itemized by date, share amount, and gross proceeds in the table.
Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

OLMA Rankings

OLMA Latest News

OLMA Latest SEC Filings

OLMA Stock Data

1.88B
76.26M
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO